Antral Helicobacter Pylori Infection, Hypergastrinemia and Peptic Ulcers: Effect of Eradicating the Organism
Open Access
- 30 January 1993
- journal article
- clinical trial
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 8 (1) , 19-25
- https://doi.org/10.3904/kjim.1993.8.1.19
Abstract
A randomized prospective study on the response of fasting serum gastrin concentrations in peptic ulcer patients was performed in order to test the hypothesis that H. pylori infection in the gastric antrum increases gastrin release, and to examine whether the high fasting serum gastrin concentrations respond to treatment that eradicates H. pylori. One hundred and twenty-seven patients with gastric or duodenal ulcer were included in this study. Patients were divided into three groups on the basis of antral H. pylori status and therapeutic modalities. The first group, 58 patients infected by H. pylori, was treated with metronidazole and tripotassium dicitrato bismuthate combined with ranitidine and mylanta. The second group, 40 patients also infected by H. Pylori, was treated with ranitidine and mylanta. The third group, 29 patients, free of H. pylori infection, was designed to evaluate the influence of H2-receptor antagonist on the change of gastrin. When ulcers were completely healed, changes of gastrin concentrations and H. pylori status were re-examined. H. pylori was eradicated in all patients who have received antibacterial therapy in 4 weeks, and serum gastrin concentrations were significantly decreased after eradication of the organism both in gastric and in duodenal ulcer diseases. (Gastric ulcer: 129.3±47.0 pg/ml before and 63.7±21.6 pg/ml after treatment. Duodenal ulcer: 108.3±35.0 pg/ml and 66.5±21.9 pg/ml, respectively. Total: 112.7±38.2 pg/ml vs 66.0±21.6 pg/ml) (p0.05) None of the patients who were initially H. pylori-negative has been reinfected during the period of the study, and their serum gastrin concentrations were not changed. (Gastric ulcer: 69.8±38.0 pg/ml. Total: 63.2±31.1 pg/ml. Duodenal ulcer: 55.1±17.6 pg/ml vs 55.8±13.8 pg/ml. Total: 63.2±31.1 pg/ml vs 63.4±30.0 pg/ml) Four- to six-week therapy of H2-receptor antagonist and antacid had no influence on serum gastrin concentrations. On the basis of the above results, we confirmed that the chronic infection of H. pylori of gastric antrum in peptic ulcer patients causes increased release of serum gastrin, and eradication of the organism results in a significant fall in serum gastrin concentrationsKeywords
This publication has 17 references indexed in Scilit:
- Suppression of Helicobacter pylori reduces gastrin releasing peptide stimulated gastrin release in duodenal ulcer patients.Gut, 1992
- Effect of Helicobacter pylori on Serum Pepsinogen I and Plasma Gastrin in Duodenal Ulcer PatientsScandinavian Journal of Gastroenterology, 1992
- Is Helicobacter pylori associated hypergastrinaemia due to the bacterium's urease activity or the antral gastritis?Gut, 1991
- Antral Helicobacter pylori, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism.BMJ, 1989
- CAMPYLOBACTER PYLORI AND DUODENAL ULCERS: THE GASTRIN LINKThe Lancet, 1989
- AMOXYCILLIN PLUS TINIDAZOLE FOR CAMPYLOBACTER PYLORI GASTRITIS IN CHILDREN: ASSESSMENT BY SERUM IgG ANTIBODY, PEPSINOGEN I, AND GASTRIN LEVELSThe Lancet, 1989
- PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORIThe Lancet, 1988
- CAMPYLOBACTER PYLORI AND RECURRENCE OF DUODENAL ULCERS— A 12-MONTH FOLLOW-UP STUDYThe Lancet, 1987
- Pyloric Campylobacter infection and gastroduodenal diseaseThe Medical Journal of Australia, 1985
- DIFFERENCE IN RELAPSE RATES OF DUODENAL ULCER AFTER HEALING WITH CIMETIDINE OR TRIPOTASSIUM DICITRATO BISMUTHATEThe Lancet, 1981